Testosterone Cypionate Compassionate Use and Expanded Access

What Is Testosterone Cypionate and Who Qualifies for Special Access?

Testosterone cypionate is a long-acting esterified androgen administered by intramuscular injection. The FDA approved it for the treatment of primary and hypogonadotropic hypogonadism in males, and it appears on the FDA's list of approved drug products under multiple generic holders [1]. Documented testosterone deficiency, confirmed by two morning serum testosterone measurements below the laboratory reference range (typically <300 ng/dL per Endocrine Society criteria), is the standard clinical threshold for covered prescribing [2].

Who Gets Considered for Expanded Access?

Expanded access, sometimes called compassionate use, is an FDA regulatory mechanism allowing patients with serious or life-threatening conditions to receive investigational or otherwise restricted therapies outside a clinical trial [3]. For testosterone cypionate specifically, the drug is already FDA-approved, so true expanded access under 21 CFR Part 312 Subpart I applies mainly in two scenarios: a patient requires a specific compounded concentration not commercially available, or an investigational formulation (for example, a novel delivery system) is being studied and the patient cannot enroll in the trial.

How the FDA Defines "Serious Condition" for Testosterone

The FDA's expanded access guidance defines a serious condition as one that causes substantial impairment in daily functioning [3]. Severe symptomatic hypogonadism, including muscle wasting associated with HIV, chronic opioid-induced androgen deficiency, or pituitary-damage-related testosterone deficiency, meets this threshold in most clinical assessments.

Physician Responsibilities Under Expanded Access

The treating physician must submit FDA Form 3926 for individual patient expanded access and obtain an IND (Investigational New Drug) exemption if the formulation is not commercially approved [4]. The FDA typically responds to emergency individual-patient requests within 24 hours and to non-emergency requests within 30 days [3].

FDA Expanded Access: Step-by-Step Process

The FDA's expanded access framework for individual patients involves four concrete steps, and completing them correctly determines how fast a patient receives the drug [3].

Step 1: Physician Submits FDA Form 3926

The attending physician completes FDA Form 3926, documenting the patient's diagnosis, the specific testosterone product requested, the justification for expanded access, and the proposed monitoring plan. The form is submitted directly to CDER's Division of Drug Information [4]. No patient self-submission is permitted for Schedule III controlled substances.

Step 2: IRB Review

An Institutional Review Board must review and approve the individual patient expanded access request before treatment begins, unless the FDA grants an emergency exemption [3]. Community physicians without institutional IRB access may use a commercial IRB service; turnaround times average 5 to 10 business days.

Step 3: Drug Sourcing and DEA Compliance

Because testosterone cypionate is a DEA Schedule III controlled substance under 21 USC 812, the prescribing physician's DEA registration must authorize Schedule III dispensing [5]. Compounding pharmacies that produce non-commercially-available concentrations must hold a valid DEA manufacturer's registration and comply with USP <797> sterile compounding standards.

Step 4: Ongoing Safety Reporting

Physicians using expanded access must submit annual safety reports to the FDA and report any serious adverse events within 15 days [3]. The most clinically relevant adverse events for testosterone include erythrocytosis (hematocrit >54%), polycythemia, and cardiovascular events documented in the TOM trial [6].

Patient Assistance Programs for Testosterone Cypionate

Generic testosterone cypionate is manufactured by several companies, and assistance program availability shifts as manufacturer contracts change. The field as of mid-2025 includes the following concrete options [7].

Pfizer RxPathways

Pfizer manufactures branded Depo-Testosterone (testosterone cypionate 100 mg/mL and 200 mg/mL). Pfizer RxPathways offers free or reduced-cost medication to patients who meet income eligibility criteria, typically household income at or below 400% of the Federal Poverty Level (FPL) [7]. Patients must have no prescription drug insurance or have exhausted Medicare Part D coverage. Applications are submitted at pfizerrxpathways.com or by calling 1-844-989-PATH.

NeedyMeds and State Programs

NeedyMeds (needymeds.org) aggregates patient assistance programs across all manufacturers and lists state pharmaceutical assistance programs that may cover testosterone cypionate for low-income adults [8]. A 2021 analysis published in JAMA found that 13% of adults with a chronic condition requiring branded therapy used a patient assistance program, though generic penetration in TRT has reduced that figure for testosterone specifically [9].

Manufacturer Samples and 340B Programs

Federally Qualified Health Centers (FQHCs) and certain nonprofit clinics participate in the 340B Drug Pricing Program, which allows them to purchase outpatient drugs at significantly reduced ceiling prices [10]. Patients receiving care at a 340B-covered entity may access testosterone cypionate at costs approaching the 340B ceiling price, which is calculated as the average manufacturer price minus a statutory rebate.

The HealthRX Access Decision Framework (see figure below, pending editorial insertion) maps a patient's insurance status, income level, and clinical diagnosis to the most cost-efficient access pathway, reducing time-to-prescription by an estimated two to three steps compared to ad hoc searching.

How to Get Testosterone Cypionate Cheaper: Discount Cards and Pharmacy Strategies

For patients with commercial insurance that does not cover testosterone cypionate, or who pay out of pocket, pharmacy discount programs reduce the actual cash price substantially [11].

GoodRx and Similar Programs

GoodRx pricing for generic testosterone cypionate 200 mg/mL (10 mL vial) ranged from approximately $25 at Costco Pharmacy to $112 at some retail chains as of June 2025, based on publicly available GoodRx data. Patients should compare prices across at least three pharmacies before filling, because price variation for this specific product exceeds 300% in some ZIP codes [11].

NeedyMeds, RxSaver, and Blink Health offer comparable discount structures. Discount cards cannot be combined with insurance benefits for the same claim; patients should confirm with the pharmacist which payment method produces the lower net cost.

90-Day Supply Strategies

Mail-order pharmacies affiliated with insurance plans typically dispense a 90-day supply for the equivalent of a 60-day copay. For patients on stable TRT dosing (commonly 100 mg/mL testosterone cypionate 1 mL injected every 7 days), a 90-day supply requires three 10 mL vials, and the per-unit cost falls when purchasing larger quantities where pharmacy rules allow [12].

Therapeutic Alternatives and Formulary Substitution

Testosterone enanthate, a chemically similar ester with equivalent clinical efficacy per a 2004 comparative pharmacokinetic study [13], may be priced lower or placed on a more favorable formulary tier at a given pharmacy. Discussing therapeutic substitution with the prescribing physician is appropriate when cost is the primary access barrier.

Insurance Coverage, Prior Authorization, and Appeals

Most commercial plans cover testosterone cypionate for FDA-approved indications when clinical documentation supports the diagnosis. The Endocrine Society's 2018 clinical practice guideline specifies that two morning serum testosterone measurements below the lower limit of normal, combined with consistent clinical symptoms, constitute the diagnostic threshold required for coverage [2].

Prior Authorization Requirements

A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that 68% of TRT prescriptions required prior authorization under commercial plans, with an average processing time of 3.2 days for electronic submissions [14]. Physicians should include the following in prior authorization submissions: two testosterone lab values with collection times before 10 a.m., a completed symptom questionnaire, and documentation that the patient does not have active prostate cancer or untreated obstructive sleep apnea [2].

Appealing a Denial

Patients whose prior authorization is denied have the right to an internal appeal and, if unsuccessful, an external independent review under the Affordable Care Act [15]. The FDA's MedWatch program is not the appropriate channel for coverage disputes; denials should go through the insurer's formal appeals process first, followed by a state insurance commissioner complaint if the external review is also denied.

Medicare Part D Coverage

Medicare Part D covers testosterone cypionate under most plan formularies when the prescribing physician documents hypogonadism. The Extra Help (Low Income Subsidy) program reduces or eliminates Part D copays for beneficiaries with income at or below 150% FPL [16]. Applications for Extra Help are submitted through the Social Security Administration.

Can I Use HSA or FSA for Testosterone Cypionate?

Yes. Testosterone cypionate prescribed by a licensed physician for a diagnosed medical condition is an eligible expense under a Health Savings Account (HSA) or Flexible Spending Account (FSA), per IRS Publication 502 [17]. The prescription requirement is absolute; over-the-counter testosterone products do not qualify.

HSA Rules Specific to TRT

HSA funds can be used for the drug cost, the injection supplies (syringes, needles, alcohol swabs), the laboratory tests required for monitoring (CBC, testosterone levels, PSA), and the physician visit fees associated with TRT management [17]. The IRS does not require itemized receipts for amounts under $75, but retaining documentation is standard practice for audit readiness.

FSA Grace Periods and Run-Out

Flexible Spending Accounts typically have a use-it-or-lose-it rule with either a 2.5-month grace period or a $610 rollover allowance (2024 IRS limit) [17]. Patients planning to start TRT near the end of a plan year should confirm their FSA balance and timing with their HR department to avoid forfeiting funds.

LPFSA Eligibility

A Limited Purpose FSA (LPFSA), which pairs with an HSA for dental and vision, does not cover prescription drugs. Patients with an LPFSA cannot use it for testosterone cypionate; only a standard FSA or HSA applies [17].

Compounded Testosterone Cypionate: Access, Legality, and Safety

Compounded testosterone cypionate occupies a distinct regulatory space from FDA-approved commercial products. Patients sometimes seek compounded versions to obtain non-standard concentrations (for example, 40 mg/mL for subcutaneous dosing) or to reduce cost.

503A vs. 503B Compounders

Under the Drug Quality and Security Act of 2013, compounding pharmacies operate under either Section 503A (patient-specific prescriptions) or Section 503B (outsourcing facilities that may produce larger batches without individual prescriptions) [18]. The FDA maintains a list of registered 503B outsourcing facilities at fda.gov; patients should verify that any pharmacy providing compounded testosterone holds current registration [18].

FDA Safety Alerts on Compounded Testosterone

The FDA has issued safety communications regarding compounded testosterone products, noting risks from non-sterile preparation and incorrect potency [19]. A 2020 FDA analysis of compounded testosterone samples found that 9 of 36 samples (25%) failed sterility or potency testing [19]. Patients using compounded testosterone should source exclusively from 503B-registered facilities with current certificates of analysis.

Subcutaneous Administration Research

A 2017 study published in the Journal of Clinical Endocrinology and Metabolism (N=37) found that subcutaneous testosterone cypionate at 50 mg/week produced mean trough testosterone levels of 492 ng/dL with less peak-to-trough variability than standard intramuscular dosing [20]. This finding drives demand for lower-concentration compounded formulations that are not available commercially.

Clinical Monitoring Requirements During TRT

Access to testosterone cypionate does not end with the prescription. Ongoing monitoring is a regulatory and clinical requirement, and failing to monitor appropriately is the most common reason insurers use to terminate TRT coverage [2].

Baseline and Follow-Up Labs

The Endocrine Society guideline recommends obtaining hematocrit, PSA (in males over 40), and serum testosterone at 3 and 6 months after initiating therapy, then annually thereafter [2]. A hematocrit above 54% requires dose reduction or temporary discontinuation per the guideline's explicit language: "We suggest that clinicians withhold testosterone therapy if the hematocrit is greater than 54%" [2].

Cardiovascular Considerations

The TOM (Testosterone in Older Men with Mobility Limitations) trial (N=209) was stopped early because of a statistically significant increase in cardiovascular adverse events in the testosterone arm compared with placebo (23 events vs. 5 events, P<0.001) [6]. This trial specifically enrolled men with mobility limitations and multiple comorbidities; the cardiovascular risk profile in younger, healthier hypogonadal men differs, but clinicians should document a cardiovascular risk discussion in the chart before initiating therapy.

Bone Density Monitoring

For patients with hypogonadism of more than 12 months' duration, the Endocrine Society recommends dual-energy X-ray absorptiometry (DXA) at baseline and every 1 to 2 years during TRT, given the well-documented relationship between testosterone deficiency and bone mineral density loss [2].

Telehealth Access to Testosterone Cypionate Prescriptions

Since 2020, the DEA has permitted Schedule III controlled substances to be prescribed via telehealth without an initial in-person visit, under the COVID-19 public health emergency flexibilities. As of 2025, the DEA's proposed rules on telemedicine prescribing of controlled substances remain under regulatory review [21].

Current DEA Telemedicine Rules

The DEA's March 2023 proposed rule would require a one-time in-person evaluation before a practitioner could prescribe Schedule III, V controlled substances via telemedicine alone [21]. A final rule had not been published as of the date of this article's last review (July 2025). Patients using telehealth platforms for TRT should confirm with their provider whether an in-person visit is required under current DEA guidance in their state.

State-Level Prescribing Requirements

Several states impose stricter prescribing requirements for testosterone than federal minimums. Texas, for example, requires a physical examination before any Schedule III testosterone prescription, regardless of federal telehealth flexibilities. Patients should verify state-specific rules through their state medical board website.